Haemonetics Corporation reported second-quarter fiscal 2027 results with net revenue of $358 million, a 9% increase year-over-year, driven by strong growth in its Apheresis segment. Diluted earnings per share reached $1.00, up from $0.81 in the prior year period, while adjusted diluted EPS rose 6.3% to $1.35. The company also updated its fiscal 2027 guidance, raising full-year organic revenue growth expectations to a range of 6-9%, compared to the previous estimate of 4-7%. Operating cash flow for the quarter was $128 million, supporting free cash flow of $104 million. Haemonetics is a global medical technology company specializing in blood management and apheresis technologies.
